Top 30 Life Science Startup Investors in Australia (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Main Sequence Ventures
VC Fund
|
3 | Australia, United States, Philippines | Seed, Series A, Series B | Software, Artificial Intelligence, Manufacturing | $1M–$72M |
|
Catalio Capital Management
VC Fund
|
2 | United States, Switzerland, Israel | Series A, Series B | Biotechnology, Health Care, Life Science | $15M–$150M |
|
Tin Alley Ventures
VC Fund
|
2 | Australia, Philippines | Pre-Seed, Seed, Series B | Biotechnology, Medical, Software | $430k–$2.9M |
|
Flintco, LLC
VC Fund
|
1 | Australia | Seed | Real Estate, Life Science, Property Management | |
|
Possible Ventures
VC Fund
|
1 | Germany, United States, Australia | Seed, Pre-Seed, Series A | Software, Biotechnology, Information Technology | $586k–$47M |
|
ONE Innovators
VC Fund
|
1 | Japan, Australia | Series B, Seed, Series A | AgTech, Sensor, Farming | |
|
Uniseed Ventures
VC Fund
|
1 | Australia, United States, United Kingdom | Series A, Seed | Biotechnology, Health Care, Manufacturing | $381k–$16M |
|
Harry Debney
Angel
|
1 | Australia | Series A | Life Science, Biotechnology, Venture Capital | |
|
Riverlane Capital
VC Fund
|
1 | Australia | Series A | Life Science, Biotechnology, Venture Capital | |
|
Icehouse Ventures
VC Fund
|
1 | New Zealand, United States, United Kingdom | Seed, Series A | Software, SaaS, Information Technology | $650k–$19M |
|
Bioplatforms Australia
VC Fund
|
1 | Australia | Pre-Seed | AgTech, Farming, Agriculture | |
|
Annie Hill
Angel
|
1 | Australia | Seed | Aquaculture, Life Science, Biotechnology | |
|
Digitalis Ventures
VC Fund
|
1 | United States, United Kingdom, China | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $1.5M–$132M |
|
AbbVie Biotech Ventures
VC Fund
|
1 | United States, China, Italy | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6M–$115M |
|
OneVentures
VC Fund
|
1 | Australia, United States, Israel | Series A, Debt Financing | Software, Health Care, Biotechnology | $1M–$20M |
|
Medical Research Commercialisation Fund (MRCF)
VC Fund
|
1 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $1.3M–$16M |
|
Uniseed
VC Fund
|
1 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Manufacturing, Health Care | $471k–$22M |
|
Skalata
VC Fund
|
1 | Australia, United States, United Kingdom | Pre-Seed, Seed | Software, Information Technology, Artificial Intelligence | $125k–$2.3M |
|
Accelerating Commercialisation - AusIndustry
VC Fund
|
1 | Australia | Grant, Pre-Seed | Software, SaaS, AgTech | $153k–$472k |
|
Churchill Asset Management
VC Fund
|
1 | United States, Canada, Australia | Debt Financing, Private Equity, Series A | Health Care, Manufacturing, Food and Beverage | |
|
Breakthrough Victoria
VC Fund
|
1 | Australia, United States, Philippines | Seed, Venture - Series Unknown, Series A | Health Care, Manufacturing, Biotechnology | $500k–$35M |
|
Antler
VC Fund
|
1 | Singapore, Australia, United Kingdom | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $100k–$29M |
|
Brandon Capital
VC Fund
|
1 | Australia, United Kingdom, United States | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $673k–$81M |
|
Artesian VC
VC Fund
|
1 | Australia, United States, Hong Kong | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Health Care | $70k–$15M |
|
Time Ventures
VC Fund
|
1 | United States, Canada, Germany | Series A, Series B, Seed | Software, Information Technology, Artificial Intelligence | $3.1M–$450M |
|
Paul Little’s family office
VC Fund
|
1 | Australia | Seed, Series A | E-Commerce, Real Estate, Life Science | |
|
Parkview International
VC Fund
|
1 | Australia, United States | Series A, Series C | Pet, Medical, Veterinary | |
|
Alberici
VC Fund
|
1 | Australia | Seed | Real Estate, Life Science, Property Management | |
|
Alium Capital
VC Fund
|
1 | Australia, United States, Hong Kong | Series A, Series B, Seed | Software, FinTech, Financial Services | $500k–$465M |
|
The March Group
VC Fund
|
1 | United States, Denmark, Australia | Series A, Seed, Series C | Biotechnology, SaaS, AgTech | $4.7M–$33M |
| Access all 60 investors in Australia Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Manufacturing
- Stage:Seed, Series A, Series B
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 130
- Round size: Seed $1M–$7M; Series A $4.5M–$30M; Series B $13M–$72M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $303M in 2023
Portfolio highlights
- Varden — FILM-FREE BARRIER COATING
- Andromeda Robotics — At Andromeda, our personalised robot companions are helping Australian aged care teams bring joy and connection to residents to improve wellbeing.
- Gilmour Space Technologies — Gilmour Space is a rocket company in Australia that is developing and launching low-cost small satellite launch vehicles. All orbits, all planets: https://www.gspacetech.com
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B
- Geography: United States, Switzerland, Israel
Investor stats
- Total investments: 142
- Round size: Series A $15M–$150M; Series B $26M–$130M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- OSPRI — Multiplex qPCR reagent kits for assay development, biomarker discovery, and translational research. 120+ configurations across a broad range of research areas. Extraction-free. Customizable. For Research Use Only.
- Ratio Therapeutics — Ratio is a privately held discovery-stage biotechnology company that utilizes a suite of technologies licensed from Cornell University to develop best-in-class targeted radiotherapeutics for the treatment of metastatic cancers.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.
Show more...Investment focus
- Industry: Biotechnology, Medical, Software
- Stage:Pre-Seed, Seed, Series B
- Geography: Australia, Philippines
Investor stats
- Total investments: 7
- Round size: Pre-Seed $430k–$2.9M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- i14 — We are i14 — we sit at the intersection of Computational Cognitive Science and AI research, and have developed a new class of models called Laplace Sequence Models that are an order of magnitude faster and more efficient and multiples more accurate than the transformer. We’ve also built a foundation model platform that allows organisations tocreate private, domain-specific expert models deployable across any environment (on-prem, at the edge, on device, in a private cloud, or hosted by i14). Our research lab continues to push beyond many of the limitations of current AI, and has a host of research projects which are continually integrated to update our foundation model platform. We recently closed a $4M initial round and are preparing for the next round.
- Mirugen — Mirugen is a preclinical biotechnology company (re)programming cells to unlock innate cellular repair mechanisms.
- Kronus — Full-stack development infrastructure for safety-critical systems.
Flintco provides innovative construction solutions with an unrelenting focus on quality, safety, cost and schedule.
Show more...Investment focus
- Industry: Real Estate, Life Science, Property Management
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- LCG Capital Management — LCG Capital Management is a full-service commercial real estate firm providing integrated solutions across the real estate lifecycle.
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, United States, Australia
Investor stats
- Total investments: 170
- Round size: Seed $1.5M–$10M; Pre-Seed $586k–$3.5M; Series A $9.7M–$47M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Mkind — Mkind builds intelligent robots for high-mix manufacturing, developing advanced automation solutions that can adapt to diverse production requirements, improve operational efficiency, and support manufacturers in handling complex, low-volume, and frequently changing product lines.
- Orbem — Transform biological imaging with AI-powered MRI technology. Non-invasive solutions for poultry, fruits, nuts, and health. Building a sustainable future.
- Transition Metal Solutions — Transition harnesses wild microbial communities to recover copper and other critical metals from low-grade mining resources.
The global imperative of achieving net-zero emissions by 2050 demands innovative solutions across all nations, including Japan. Recognizing this urgency, ONE Innovators has established a dedicated venture capital fund focused on the carbon-neutral sector.
Show more...Investment focus
- Industry: AgTech, Sensor, Farming
- Stage:Series B, Seed, Series A
- Geography: Japan, Australia
Investor stats
- Total investments: 4
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Archeda — Archeda is an IT firm that analysis of natural environments using remote sensing data.
- Creattura — Creatura assists companies in reducing greenhouse gas emissions by generating and distributing carbon credits and promoting the adoption of renewable energy sources.
- Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.
Uniseed is Australia's first, and longest running, university owned venture fund. Established in 2000, we are owned by 9 universities plus CSIRO (behind over 60% of Australia's research) and fund deep-tech spinouts through to global scale.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 57
- Round size: Seed $381k–$4.2M; Series A $1.3M–$16M
- Lead/follow: 12% lead, 88% follow
- Last fund: May invest from a new fund soon — raised $14M in 2017
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
CEO @ Costa Group
Show more...Investment focus
- Industry: Life Science, Biotechnology, Venture Capital
- Stage:Series A
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
Long-term owner-operators of great Australian businesses.
Show more...Investment focus
- Industry: Life Science, Biotechnology, Venture Capital
- Stage:Series A
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
Icehouse Ventures is an early-stage venture capital firm. We exist to back the world's bravest Kiwi founders, launching global companies from New Zealand.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Seed, Series A
- Geography: New Zealand, United States, United Kingdom
Investor stats
- Total investments: 252
- Round size: Seed $650k–$4.9M; Series A $2.5M–$19M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $69M in 2021
Portfolio highlights
- Hnry — Hnry automatically pays and files all taxes for contractors, freelancers, and sole traders, so they never have to think about tax again.
- Vessev — Electric hydrofoiling vessels built for commercial use. Quiet, efficient, and better for the world.
- Wellumio — Wellumio is a medical technology company redefining the boundaries of clinical imaging. We’re fusing technology, design innovation, and medical expertise to create new diagnostic pathways that support the timely delivery of urgent stroke care.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Bioplatforms Australia is a non-profit entity that supports life science research in genomic, proteomics, metabolomics, and bioinformatics.
Show more...Investment focus
- Industry: AgTech, Farming, Agriculture
- Stage:Pre-Seed
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.
Annie Hill
Show more...Investment focus
- Industry: Aquaculture, Life Science, Biotechnology
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Fremantle Seaweed — Fremantle Seaweed is committed to combating climate change by growing Asparagopsis along with a variety of other local seaweeds ocean grown in local Western Australia waters.
Engineering solutions to complex problems in health through venture investment and company creation.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 113
- Round size: Seed $1.5M–$15M; Series A $8.6M–$66M; Series B $13M–$132M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Somatix — A fully comprehensive monitoring solution with unique smartband technology. Solutions for SNFs, senior living, healthcare systems, and smoking cessation.
- Girihlet — Girihlet is a provider of rapid and accurate deep sequencing services with a unique focus on developing novel technologies. Girihlet currently specializes in inexpensively sequencing and analyzing mtDNA and T cell receptors using novel, bias-free methods in order to harness their power as biomarkers for diagnostics in a variety of disorders.
- Omni — Omni provides Healthy Vegan Dog Food in the UK, made by vets to be a nutritionally complete meal for your dog. Feed your dog all the goodness of plants backed by science.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, Italy
Investor stats
- Total investments: 49
- Round size: Series A $6M–$53M; Series B $12M–$85M; Series C $39M–$115M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
- Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
- DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
OneVentures is a later-stage venture capital firm focused on scaling Technology and Healthcare companies through growth equity and credit. The firm's role extends far beyond investment, as the firm actively guides companies toward achieving their next critical milestones. By leveraging decades of global experience and operational expertise,OneVentures accelerates growth and helps shape the future of its portfolio companies.A global growth focus drives their investment selection, with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Debt Financing
- Geography: Australia, United States, Israel
Investor stats
- Total investments: 80
- Round size: Series A $1.5M–$20M; Debt Financing $1M–$6.7M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $145M in 2022
Portfolio highlights
- me&u — me&u is an online ordering and payment application designed to order meals. They provide communication technology to order and pay through mobile phones at restaurants. Their process of ordering with waiters and splitting bills that enable users to order their food and pay bills through a digital payment platform.
- Truescope — Make better informed communications decisions with Truescope. Harnessing millions of media posts every day to deliver you real-time information that influences your business strategy.
- Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 26
- Round size: Series A $1.3M–$13M; Series B $6.4M–$16M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- MycRx — MecRx is a drug development company that works on new treatments for cancer and novel mechanism of action antibiotics. Using proprietary “hit identification” technology, MecRx is developing inhibitors of cMyc, a protein that is deregulated in over 50% of all human cancers. MecRx draws on the expertise of the Peter MacCallum Cancer Centre and CSIROand is headquartered in Melbourne, Australia.MecRx was founded in 2013 by an ex-pharma/biotech team. MecRx is run as a virtual company based in Melbourne, Australia and its shareholders and service providers include the Peter MacCallum Cancer Institute and CSIRO. The company secured $5m Series A investment from the MRCF (www.mrcf.com.au) and CSIRO in 2015.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Health Care
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 86
- Round size: Seed $600k–$3.5M; Series A $1.6M–$16M; Series B $471k–$22M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- DeteQt — Semiconductor chip-based quantum magnetic field sensors using diamond - navigation, mining, medical imaging
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Plasmaleap — Plasmaleap is a plasma technology company that manufactures and sells zero-emissions chemical reactors designed for industrial and energy applications. The company develops reactor systems that use plasma processes to enable chemical production and transformation without relying on conventional combustion methods. Its technology supports sectorssuch as clean fuels, chemical manufacturing, and materials processing by offering electrified reactor solutions that can be integrated into existing industrial workflows. Plasmaleap designs modular systems that allow operators to deploy plasma reactors for on-site production and conversion of feedstocks using electricity as the primary energy input. The company also provides engineering support and technical integration services to help customers incorporate its reactor technology into commercial operations. Through its plasma-based approach, Plasmaleap focuses on enabling chemical processes that align with decarbonization and emissions reduction objectives across multiple industries.
Giving Australian founders access to the education, capital and networks needed to build significant, sustainable, global businesses of the future.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Pre-Seed, Seed
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 88
- Round size: Seed $135k–$2.3M; Pre-Seed $125k–$406k
- Lead/follow: 80% lead, 20% follow
- Last fund: Likely still investing — raised $18M in 2021
Portfolio highlights
- Enrola — Looking for online training courses? Discover the perfect course for you with our easy course advisor quiz. Get individual guidance and apply directly.
- Paperly — Paperly helps companies streamline processes, compliance, and approvals in one platform. Gain real-time visibility and empower your teams to work with clarity and confidence.
- Cor — Obi by Cor is the leading voice AI agent for customer onboarding and user activation. It uses voice and on-screen awareness to guide users, share best practices, and answer questions in real time.
A grant program offered by AusIndustry as part of the Australian Government’s National Innovation and Science Agenda
Show more...Investment focus
- Industry: Software, SaaS, AgTech
- Stage:Grant, Pre-Seed
- Geography: Australia
Investor stats
- Total investments: 6
- Round size: Grant $153k–$472k
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Getmee — Getmee AI is the leading AI-powered coaching app for communication and employability. We help you improve your English, soft skills, and interview confidence!
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Hearables 3D — Scale your custom-fit volumes and solve dental lab technician shortage with AI and automation solutions.
Churchill is a leading capital provider for private equity-owned, middle market companies. We provide first lien, unitranche, second lien and mezzanine debt, in addition to equity co-investments, secondary solutions and private equity fund commitments.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Food and Beverage
- Stage:Debt Financing, Private Equity, Series A
- Geography: United States, Canada, Australia
Investor stats
- Total investments: 33
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- One Physics — Apex Physics Partners serves medical centers and physics practices by offering therapy and diagnostic services and support for medical physics practices.
- Action Behavior Centers — Action Behavior Centers is a center-based provider of ABA therapy for children on the moderate to severe end of the autism spectrum.
- Choice Insurance Agency — Choice Insurance offers insurance solutions for your home, auto, business, and life. Discover how we can help to safeguard your financial future. Call Us.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!The Breakthrough Victoria Fund is a $2 billion investment by the Victorian Government to drive investment in research and innovation.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Biotechnology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 55
- Round size: Seed $708k–$6.8M; Series A $4M–$35M; Venture - Series Unknown $500k–$30M
- Lead/follow: 53% lead, 47% follow
Portfolio highlights
- AlleSense — AlleSense has developed a unique and novel solution to label-free imaging, the NanoMslide.
- Mental Jam — We are a games studio dedicated to creating impactful experiences that explore mental health.
- Deftbiotech — Deftbiotech is a biotech startup developing peptide-based antifungal treatments for nail and skin infections.
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Singapore, Australia, United Kingdom
Investor stats
- Total investments: 2214
- Round size: Seed $159k–$4.6M; Pre-Seed $100k–$645k; Series A $4.1M–$29M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $72M in 2024
Portfolio highlights
- iiba — Iiba is a geospatial platform that specializes in providing location information related to child-rearing.
- Two — Buy Now, Pay Later for your business customers. Two makes it easy and safe to offer invoice as a payment method on your e-commerce site.
- Homethings — Single-use plastic is bonkers. Homethings makes cleaning products that make sense. No more shipping water in plastic bottles. We send non toxic cleaning tabs so that you can refill over and over again using your tap.
Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United Kingdom, United States
Investor stats
- Total investments: 79
- Round size: Seed $673k–$9.7M; Series A $5.2M–$81M; Series B $6.4M–$68M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $210M in 2019
Portfolio highlights
- Longas — Longas Technologies, a Next Generation Sequencing (NGS) technology developer, has provided details on its Morphoseq™ library prep and associated software technology at the ‘Sequencing, Finishing and Analysis.
- Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
- Cincera Therapeutics — Cincera Therapeutics is a privately held biotechnology company.
Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States, Hong Kong
Investor stats
- Total investments: 407
- Round size: Seed $101k–$5M; Pre-Seed $70k–$1M; Series A $2.3M–$15M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- LivedCX® — LIVEDCX: Advanced AI technology for contact centre leaders who must simplify complexity to create growth.
- Andromeda Robotics — At Andromeda, our personalised robot companions are helping Australian aged care teams bring joy and connection to residents to improve wellbeing.
- Infiction labs — SPARC 1.2 is a solar panel robotic cleaning system designed and developed by Infiction Labs Pvt Ltd for commercial solar plants.
Time Ventures is an investment fund for Marc Benioff. The company looks to invest in theB2B, hospitality, non-financial services, and commercial products and services sectors.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: United States, Canada, Germany
Investor stats
- Total investments: 57
- Round size: Seed $3.1M–$450M; Series A $10M–$80M; Series B $20M–$140M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Laurel — Time by Ping frees lawyers from timekeeping so they can focus on their work, and firms can understand where time is being spent.
- June.ai — Discover June, a digital communication hub that replaces your email experience. June creates a new world for your existing email that gives you more control, interactivity and efficiency.
- June — Transform enterprise system deployment with June. AI-driven implementation for Salesforce, Snowflake, SAP & more. No downtime, faster delivery, full control.
Paul Little’s family office operates as an investment firm.
Show more...Investment focus
- Industry: E-Commerce, Real Estate, Life Science
- Stage:Seed, Series A
- Geography: Australia
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
- EstateXchange — Simplest way to settle deceased estates securely. Save time with estates administration. For lawyers, banks & more. Deliver faster outcomes for all.
Parkview International operates as a single-family office.
Show more...Investment focus
- Industry: Pet, Medical, Veterinary
- Stage:Series A, Series C
- Geography: Australia, United States
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Petfolk — Petfolk's world-class animal hospitals & pet care centers offer virtual, in-person & urgent veterinary care with a pet-parent-focused approach. Learn more!
- Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
Alberici is a diversified construction company recognized for superior quality and customer service. With operations throughout North America and clients around the world, they offer general contracting, construction management, and design-build solutions across a broad spectrum of industrial and commercial markets.
Show more...Investment focus
- Industry: Real Estate, Life Science, Property Management
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- LCG Capital Management — LCG Capital Management is a full-service commercial real estate firm providing integrated solutions across the real estate lifecycle.
Alium Capital focuses on listed and unlisted technology investments to generate out-sized returns. The company invests in technology, innovation, and early-stage businesses, all the way through to publicly listed assets. It specializes in the fields of finance, investing, innovation, and capital.Alium Capital was founded in 2016 andheadquartered in Sydney, New South Wales.
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Series A, Series B, Seed
- Geography: Australia, United States, Hong Kong
Investor stats
- Total investments: 45
- Round size: Seed $4.5M–$10M; Series A $500k–$13M; Series B $2M–$465M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $72M in 2017
Portfolio highlights
- Boost Lab — Boost Lab provides solutions for skincare products that are cost-effective, effective, and safe.
- Koala — We're simplifying the mattress and furniture game. With free & fast delivery and a 120 night risk-free trial Australia-wide, try it out online today.
- York Street Brands — York Street Brands, formed by the merger of Boost Lab and tbh Skincare specializes in serums that target a range of skin concerns.
A venture capital fund platform committed to supporting and investing in entrepreneurs and companies developing and bringing exponential technologies to food, health and sustainability. March's investment strategy involves becoming recognized as the leading investor in critical and transformative technology solutions, and aims to achieve thisby investing into companies and funds that focus on developing core intellectual property around game-changing sustainable solutions that are aligned with globally relevant sustainability trends and benefits.
Show more...Investment focus
- Industry: Biotechnology, SaaS, AgTech
- Stage:Series A, Seed, Series C
- Geography: United States, Denmark, Australia
Investor stats
- Total investments: 7
- Round size: Seed $4.7M–$4.8M; Series A $7.2M–$33M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $2.1M in 2019
Portfolio highlights
- Digestiva — We amplifye Protein.
- EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
- Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.
Life Science Investor funding in Australia at a glance
Stats across 40 deals from 60 investors.
Access all 60 investors in Australia Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors in Australia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 60 investors investing in Australia Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!